Dr. Alex Aimetti of InVivo Therapeutics to Speak at Working 2 Walk Spinal Cord Injury Symposium
<0> InVivo TherapeuticsLauren Mitarotondo, 617-863-5510 </0>
a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced the Company’s sponsorship of the 7 annual Working 2 Walk Science & Advocacy Symposium that will take place November 1-3, 2012 in Irvine, CA.
Working 2 Walk is an annual event held by Unite 2 Fight Paralysis to bring together spinal cord injury research scientists, practitioners, investors and consumers for a lively discussion of current research and strategies that will accelerate progress toward cures for paralysis. Unite 2 Fight Paralysis is a not-for-profit organization dedicated to the realization of curative therapies.
Alex Aimetti, PhD, InVivo’s Research & Development Manager, Biomaterials, will speak on behalf of the Company at the symposium. Dr. Aimetti will present on InVivo’s scaffold and hydrogel as well as designing synthetic biomaterials for various drug delivery and tissue engineering applications. InVivo Therapeutics has developed a new treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after a traumatic spinal cord injury. The Company expects FDA approval in early 2013 to begin a clinical trial for the treatment in acute SCI.
Said Dr. Aimetti, “It is an honor to speak at this symposium and I am very excited to interact with the SCI community at Working 2 Walk. I will be discussing the benefits of using biomaterials as a viable treatment option and discuss how we have leveraged our technology to develop first-class products that will soon enter the clinic.”
InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit .
Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the expected approval of the FDA to conduct human clinical trials for the Company’s products, the expected commencement date of any approved human clinical trials, the expected size of the pilot study, the expectation that the scaffold product will be regulated under a HDE pathway, and the expected acceleration of commercialization of the Company’s products resulting therefrom. These forward-looking statements are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to obtain FDA approval to conduct human clinical trials; whether the human clinical trials produce acceptable results; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2011 and subsequent filings with the SEC.
Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The Company undertakes no obligation and expressly disclaims any duty to update such statements.